Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693.
Clin Infect Dis. 2024.
PMID: 37967326
Free PMC article.
Clinical Trial.
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Grais RF, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BA, Welebob C, Hanson ME, Simon JK.
Grais RF, et al. Among authors: welebob c.
Lancet Microbe. 2021 Feb;2(2):e70-e78. doi: 10.1016/S2666-5247(20)30198-1. Epub 2021 Feb 2.
Lancet Microbe. 2021.
PMID: 35544244
Free article.
Item in Clipboard
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BG, Welebob C, Hanson ME, Grais RF.
Simon JK, et al. Among authors: welebob c.
Vaccine. 2022 Nov 2;40(46):6599-6606. doi: 10.1016/j.vaccine.2022.09.037. Epub 2022 Oct 5.
Vaccine. 2022.
PMID: 36208978
Clinical Trial.
Item in Clipboard
Raltegravir pharmacokinetics in neonates following maternal dosing.
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.
Clarke DF, et al. Among authors: welebob c.
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.
J Acquir Immune Defic Syndr. 2014.
PMID: 25162819
Free PMC article.
Clinical Trial.
Item in Clipboard
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.
Winer RL, Harris TG, Xi LF, Jansen KU, Hughes JP, Feng Q, Welebob C, Ho J, Lee SK, Carter JJ, Galloway DA, Kiviat NB, Koutsky LA.
Winer RL, et al. Among authors: welebob c.
J Med Virol. 2009 Apr;81(4):713-21. doi: 10.1002/jmv.21450.
J Med Virol. 2009.
PMID: 19235870
Free PMC article.
Item in Clipboard
Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, Grosso AD, Welebob C, Kuter BJ; Pediatric Study Group for VAQTA.
Guerra FA, et al. Among authors: welebob c.
Pediatr Infect Dis J. 2006 Oct;25(10):912-9. doi: 10.1097/01.inf.0000238135.01287.b9.
Pediatr Infect Dis J. 2006.
PMID: 17006287
Clinical Trial.
Item in Clipboard
Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa.
Mao SS, Huang J, Welebob C, Neeper MP, Garsky VM, Shafer JA.
Mao SS, et al. Among authors: welebob c.
Biochemistry. 1995 Apr 18;34(15):5098-103. doi: 10.1021/bi00015a021.
Biochemistry. 1995.
PMID: 7711029
Item in Clipboard
Cite
Cite